Home
Live Updates
Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC : comparemela.com
Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC
PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.
Related Keywords
Italy ,
Japan ,
Riccardo Lencioni ,
Department Of Surgery ,
Critical Area Pathology ,
Druvalumab And Bevacizumab Plus Tace ,
Dotace ,
Hcc ,
Hepatocellular Carcinoma ,
Gastrointestinal Cancer ,
Gi Cancer ,
Asco Gi ,
Imfinzi ,
Avastin ,
Transarterial Chemoembolization ,
Phase 3 Emerald 1 Trial ,
Durvalumab ,
Bevacizumab ,
2024 Gastrointestinal Cancers Symposium ,
D ,
Università Di Pisa ,
comparemela.com © 2020. All Rights Reserved.